(11| cent,16| inverted exclamation mark)-9-FLUORO-11,21-DIHYDROXY-16,17-[(1-METHYLETHYLIDENE)BIS(OXY)]PREGNA-1,4-DIENE-3,20-DIONE

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (11| cent,16| inverted exclamation mark)-9-FLUORO-11,21-DIHYDROXY-16,17-[(1-METHYLETHYLIDENE)BIS(OXY)]PREGNA-1,4-DIENE-3,20-DIONE
• 英文别名: (1S,2S,4S,8S,9S,11S,13S)-12-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
• 化学式: C₂₄H₃₁FO₆
• 分子量: 434.5
• InChiKey: YNDXUCZADRHECN-TVHBQBCYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  31
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Novel triamcinolone compositions
  申请人：Elan Pharma International Ltd.

  公开号：US20040141925A1

  公开（公告）日：2004-07-22

  The invention is directed to nanoparticulate triamcinolone and/or triamcinolone derivative compositions. The triamcinolone or triamcinolone derivative particles of the composition have an effective average particle size of less than about 2 microns.

  本发明涉及纳米颗粒三苯氧胺和/或三苯氧胺衍生物组合物。组合物中的三苯氧胺或三苯氧胺衍生物颗粒的有效平均粒径小于约 2 微米。
• Triamcinolone formulations and methods for their preparation and use
  申请人：Akorn, Inc.

  公开号：US20040186084A1

  公开（公告）日：2004-09-23

  Sterile compositions comprising triamcinolone compounds (desirably, triamcinolone acetonide), systems for providing such compositions, and methods for the preparation and use of such compositions. Exemplary of the inventive compositions is a sterile aqueous composition comprising triamcinolone acetonide, wherein the sterile aqueous composition has a pH of between about 5 and 7.5 and contains no more than 1 wt. % excipients other than tonicity-adjusting agents and pH-adjusting agents.

  包含曲安奈德化合物（最好是曲安奈德丙酮）的无菌组合物、提供这种组合物的系统以及制备和使用这种组合物的方法。本发明组合物的范例是包含曲安奈德的无菌水性组合物，其中无菌水性组合物的pH值在约5至7.5之间，除补液调节剂和pH值调节剂外，所含赋形剂不超过1重量％。
• Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
  申请人：Nyce W. Jonathan

  公开号：US20070021360A1

  公开（公告）日：2007-01-25

  A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration, bronchoconstriction, lung allergy(ies) or inflammation, and abnormal levels of adenosine, adenosine receptors, sensitivity to adenosine, lung surfactant and ubiquinone, such as pulmonary fibrosis, vasoconstriction, inflammation, allergies, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, COPD, RDS, ARDS, cancer, and others. The present treatment is effectively administered by itself for conditions without known therapies, as a substitute for therapies exhibiting undesirable side effects, or in combination with other treatments, e.g. before, during and after other respiratory system therapies, radiation, chemotherapy, antibody therapy and surgery, among others. Each of the agents of this invention may be administered directly into the respiratory system so that they gain direct access to the lungs, or by other effective routes of administration. A kit comprises a delivery device, the agents and instructions for its use.